De Novo Pharmaceuticals

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment round in April 2000, followed by a second round of funding of £16.75 million in July 2001. Investors in the first round included Avlar Bioventures, Prelude Technology and Cambridge Research and Innovation Limited. Second round investors included Merlin Bioventures, Life Science Partners NV, Quester and FNI Venture Capital, as well as the industrial investors Roche and Incyte Pharmaceuticals. De Novo has already announced Drug Design Partnerships with 3 major pharmaceutical companies (Aventis, British Biotechnology and Organon), and 2 Technology Development Partnerships (with Roche and Sun Microsystems). With new facilities at Vision Park in Histon, the company is currently building a “gene-to-drug” pipeline of its own.

Contact Details: St Andrews House, 59 St Andrews St Cambridge Cambridgeshire CB2 3DD United Kingdom Tel: 01223 331984 Fax: 01223 327192 Email: anthony.williams@denovopharma.com WWW: www.denovopharma.com/

Loading...

Recent Publications by De Novo Pharmaceuticals:
De novo ligand design to partially flexible active sites: application of the ReFlex algorithm to carboxypeptidase A, acetylcholinesterase, and the estrogen receptor. Reflex is a recent algorithm in the de novo ligand design software,...	6th May, 2008	De Novo Pharmaceuticals Ltd., Compass House, Vision Park, Chivers Way,	J Chem Inf Model. 2008 Feb;48(2):296-305. Epub 2008 Jan 31. DOI Direct Link
Chemical genomics: a challenge for de novo drug design. De novo design provides an in silico toolkit for the design of novel small...	12th January, 2008	De Novo Pharmaceuticals Ltd., Vision Park, Compass House, Histon,	Mol Biotechnol. 2007 Nov;37(3):237-45. Epub 2007 Jun 30. DOI Direct Link
Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen. A de novo design approach to generating novel estrogen receptor (ER)...	9th September, 2006	De Novo Pharmaceuticals Ltd., Compass House, Vision Park, Histon,	J Chem Inf Model. 2006 Mar-Apr;46(2):642-7. DOI Direct Link
De novo ligand design to an ensemble of protein structures. We describe a combinatorial method for de novo ligand design to an...	10th August, 2006	De Novo Pharmaceuticals Ltd., Compass House, Cambridge, United Kingdom.	Proteins. 2006 Jul 1;64(1):43-59. DOI Direct Link
Exhaustive de novo design of low-molecular-weight fragments against the ATP-binding site of DNA-gyrase. We present a de novo design approach to generating small fragments in the...	29th June, 2006	De Novo Pharmaceuticals Ltd., Compass House, Vision Park, Histon,	J Chem Inf Model. 2006 May-Jun;46(3):1168-73. DOI Direct Link
→View more De Novo Pharmaceuticals research publications.

Press Releases on De Novo Pharmaceuticals:
DE NOVO LAUNCHES REFLEX, A MAJOR UPGRADE TO ITS IN SILICO DRUG DESIGN	1st September, 2005	De Novo	DE NOVO LAUNCHES REFLEX, A MAJOR UPGRADE TO ITS IN SILICO DRUG DESIGN PLATFORM   Cambridge, UK and California, USA, 19 September 2005 -

BioNews Results for De Novo Pharmaceuticals:
BGI Says it Has Used the Illumina GA for De Novo Sequencing of Two Macaque Genomes	GenomeWeb:  Nov 14 2009 12:14AM Matching: de novo pharmaceuticals
Vion Pharmaceuticals (VION) Engages Merriman Curhan Ford & Co. to Evaluate Strategic Alternatives	BioSpace:  Oct 13 2009 2:59PM Matching: de novo pharmaceuticals
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives	Montana's News Station:  Oct 13 2009 8:32AM Matching: de novo pharmaceuticals
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives	Red Orbit:  Oct 13 2009 12:42AM Matching: de novo pharmaceuticals
Cash-strapped Vion ponders its next-or last-move	FierceBiotech:  Oct 13 2009 6:55PM Matching: de novo pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more De Novo Pharmaceuticals news.

De Novo Pharmaceuticals Patents:
US Patent No.	Title
7323596	Antimicrobial agents
7241921	Bacterial enzyme inhibitors

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 773 times since April 2007, the link to the organisation's website has been followed 100 times

Recent Search Terms used to find this page: denovo pharma financing | denovo pharma financing | de novo pharmaceuticals | de novo pharmaceuticals | denovo bangalore | de novo pharmaceuticals | de novo pharmaceuticals bangalore | De Novo Phatmaceuticals Ltd | novo pharmaceuticals | novo pharmaceuticals | .

Search for more companies in Cambridge

Search for more companies in Cambridgeshire

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for De Novo Pharmaceuticals